Development of novel seeds for refractory peripheral neuropathy with iPS cell-derived megakaryocytes and platelets formulation.

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K20961
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0906:Surgery related to the biological and sensory functions and related fields
• Research Institution: Chiba University
• Principal Investigator: Mukai Michiaki 千葉大学, 大学院医学研究院, 特任助教 (40907698)
• Project Period (FY): 2021-08-30 – 2023-03-31
• Keywords: iPS細胞 / 血小板 / 巨核球 / 神経障害 / 疼痛 / 多血小板血漿

Outline of Final Research Achievements

We established a decompression model of peripheral neuropathy that more closely resembles actual clinical practice, in which decompression surgery (nerve dissection + thread removal) is performed a few days after the existing chronic constriction model is created. We examined the cellular dynamics in the nerve after decompression surgery and confirmed that decompression surgery suppressed the increase of T cells in the nerve.
Using this model, we confirmed the efficacy of iPS cell-derived platelets and megakaryocyte (iPMs) preparations in promoting recovery from neuropathic pain. In vitro experiments also showed that iPMs preparations promoted the proliferation and migration of Schwann cells, suggesting that these effects may play a role in the mechanism of action.

Free Research Field

再生医学

Academic Significance and Societal Importance of the Research Achievements

新規に作製した神経除圧術モデルは、従来のモデルに比べ、臨床に近いモデルであり、今後の末梢神経の研究に寄与できると考える。またiPM製剤が神経障害性疼痛の回復促進効果を有し、その機序がSchwann細胞を介する可能性が示唆され、今後の研究により、神経障害治療の新規治療シーズとして発展させ、社会貢献可能と考えた。